Floatz logo

Empagliflozin

Insulin Resistance Syndrome

Kobe UniversitySmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Insulin Resistance Syndrome cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Topamax
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Rosuvastatin
Dr. B. Catharine. Craven
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
SIMVASTATIN
Jaime Daniel Mondragon
Phase 4BBB

View all 50 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →